Abstract
The immune system confers protection against a variety of pathogens and contributes to the surveillance and destruction of neoplastic cells. Several cell types participate in the recognition and lysis of tumors, and appropriate immune stimulation provides therapeutic effects in malignancy. Foreign major histocompatibility complex (MHC) proteins also serve as a potent stimulus to the immune system. In this report, a foreign MHC gene was introduced directly into malignant tumors in vivo in an effort to stimulate tumor rejection. In contrast to previous attempts to induce tumor immunity by cell-mediated gene transfer, the recombinant gene was introduced directly into tumors in vivo. Expression of the murine class I H-2Ks gene within the CT26 mouse colon adenocarcinoma (H-2Kd) or the MCA 106 fibrosarcoma (H-2Kb) induced a cytotoxic T-cell response to H-2Ks and, more importantly, to other antigens present on unmodified tumor cells. This immune response attenuated tumor growth and caused complete tumor regression in many cases. Direct gene transfer in vivo can therefore induce cell-mediated immunity against specific gene products, which provides an immunotherapeutic effect for malignancy, and potentially can be applied to the treatment of cancer and infectious diseases in man.
Full text
PDF




Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brattain M. G., Strobel-Stevens J., Fine D., Webb M., Sarrif A. M. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 1980 Jul;40(7):2142–2146. [PubMed] [Google Scholar]
- Danos O., Mulligan R. C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6460–6464. doi: 10.1073/pnas.85.17.6460. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Esumi N., Hunt B., Itaya T., Frost P. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res. 1991 Feb 15;51(4):1185–1189. [PubMed] [Google Scholar]
- Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990 Feb 9;60(3):397–403. doi: 10.1016/0092-8674(90)90591-2. [DOI] [PubMed] [Google Scholar]
- Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990 Dec 15;50(24):7820–7825. [PubMed] [Google Scholar]
- Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990 Oct 1;172(4):1217–1224. doi: 10.1084/jem.172.4.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun. 1991 Aug 30;179(1):280–285. doi: 10.1016/0006-291x(91)91366-k. [DOI] [PubMed] [Google Scholar]
- Herberman R. B. Multiple functions of natural killer cells, including immunoregulation as well as resistance to tumor growth. Concepts Immunopathol. 1985;1:96–132. [PubMed] [Google Scholar]
- Hui K. M., Sim T., Foo T. T., Oei A. A. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol. 1989 Dec 1;143(11):3835–3843. [PubMed] [Google Scholar]
- Hui K., Grosveld F., Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature. 1984 Oct 25;311(5988):750–752. doi: 10.1038/311750a0. [DOI] [PubMed] [Google Scholar]
- Itaya T., Fearon E., Fiesinger T., Hunt B., Vogelstein B., Frost P. Immunogenicity of a non-class I MHC expressing murine tumor transfected with the influenza virus hemagglutinin or murine interleukin-2 genes. Cancer Immunol Immunother. 1991;33(4):267–273. doi: 10.1007/BF01744947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Itaya T., Yamagiwa S., Okada F., Oikawa T., Kuzumaki N., Takeichi N., Hosokawa M., Kobayashi H. Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld). Cancer Res. 1987 Jun 15;47(12):3136–3140. [PubMed] [Google Scholar]
- Kern D. E., Klarnet J. P., Jensen M. C., Greenberg P. D. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol. 1986 Jun 1;136(11):4303–4310. [PubMed] [Google Scholar]
- Khavari P. Cytotoxic cellular mediators of the immune response to neoplasia: a review. Yale J Biol Med. 1987 Sep-Oct;60(5):409–419. [PMC free article] [PubMed] [Google Scholar]
- Korman A. J., Frantz J. D., Strominger J. L., Mulligan R. C. Expression of human class II major histocompatibility complex antigens using retrovirus vectors. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2150–2154. doi: 10.1073/pnas.84.8.2150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985 Aug;45(8):3735–3741. [PubMed] [Google Scholar]
- Lindahl P., Leary P., Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci U S A. 1973 Oct;70(10):2785–2788. doi: 10.1073/pnas.70.10.2785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lotze M. T., Chang A. E., Seipp C. A., Simpson C., Vetto J. T., Rosenberg S. A. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA. 1986 Dec 12;256(22):3117–3124. [PubMed] [Google Scholar]
- Muul L. M., Spiess P. J., Director E. P., Rosenberg S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987 Feb 1;138(3):989–995. [PubMed] [Google Scholar]
- Nabel E. G., Gordon D., Yang Z. Y., Xu L., San H., Plautz G. E., Wu B. Y., Gao X., Huang L., Nabel G. J. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther. 1992 Dec;3(6):649–656. doi: 10.1089/hum.1992.3.6-649. [DOI] [PubMed] [Google Scholar]
- Nabel E. G., Plautz G., Nabel G. J. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990 Sep 14;249(4974):1285–1288. doi: 10.1126/science.2119055. [DOI] [PubMed] [Google Scholar]
- Nabel E. G., Plautz G., Nabel G. J. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5157–5161. doi: 10.1073/pnas.89.11.5157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oldham R. K. Natural killer cells: artifact to reality: an odyssey in biology. Cancer Metastasis Rev. 1983;2(4):323–336. doi: 10.1007/BF00048565. [DOI] [PubMed] [Google Scholar]
- Osband M. E., Ross S. Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today. 1990 Jun;11(6):193–195. doi: 10.1016/0167-5699(90)90080-s. [DOI] [PubMed] [Google Scholar]
- Powell M. B., Conta B. S., Horowitz M., Ruddle N. H. The differential inhibitory effect of lymphotoxin and immune interferon on normal and malignant lymphoid cells. Lymphokine Res. 1985 Winter;4(1):13–26. [PubMed] [Google Scholar]
- Puccetti P., Romani L., Fioretti M. C. Chemical xenogenization of experimental tumors. Cancer Metastasis Rev. 1987;6(2):93–111. doi: 10.1007/BF00052845. [DOI] [PubMed] [Google Scholar]
- Restifo N. P., Spiess P. J., Karp S. E., Mulé J. J., Rosenberg S. A. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992 Jun 1;175(6):1423–1431. doi: 10.1084/jem.175.6.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
- Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
- Russell S. J. Lymphokine gene therapy for cancer. Immunol Today. 1990 Jun;11(6):196–200. doi: 10.1016/0167-5699(90)90081-j. [DOI] [PubMed] [Google Scholar]
- Sarmiento M., Glasebrook A. L., Fitch F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol. 1980 Dec;125(6):2665–2672. [PubMed] [Google Scholar]
- Shu S., Rosenberg S. A. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol. 1985 Oct;135(4):2895–2903. [PubMed] [Google Scholar]
- Stewart M. J., Plautz G. E., Del Buono L., Yang Z. Y., Xu L., Gao X., Huang L., Nabel E. G., Nabel G. J. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther. 1992 Jun;3(3):267–275. doi: 10.1089/hum.1992.3.3-267. [DOI] [PubMed] [Google Scholar]
- Sugiura C., Itaya T., Kondoh N., Oikawa T., Kuzumaki N., Takeichi N., Hosokawa M., Kobayashi H. Xenogenization of tumor cells by transfection with plasmid containing env gene of Friend leukemia virus. Jpn J Cancer Res. 1988 Dec;79(12):1259–1263. doi: 10.1111/j.1349-7006.1988.tb01553.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tepper R. I., Pattengale P. K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989 May 5;57(3):503–512. doi: 10.1016/0092-8674(89)90925-2. [DOI] [PubMed] [Google Scholar]
- Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–3725. [PubMed] [Google Scholar]
- Wallich R., Bulbuc N., Hämmerling G. J., Katzav S., Segal S., Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985 May 23;315(6017):301–305. doi: 10.1038/315301a0. [DOI] [PubMed] [Google Scholar]
- Yoshizawa H., Sakai K., Chang A. E., Shu S. Y. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol. 1991 May;134(2):473–479. doi: 10.1016/0008-8749(91)90318-6. [DOI] [PubMed] [Google Scholar]